기업 프로필 · Healthcare

Royalty Pharma Plc

RPRX · 미국
산업
生物制药特许权
거래소
미국
국가 / 지역
USA
상장일
1993년 3월 25일
직원 수
100
웹사이트
www.royaltypharma.com
현재가
$56.66
실시간 · 2026년 10월 5일
적정 매수가
≤ $40
안전마진 진입가
베일리 성장 점수
50/100
보통
Buffett Score
58/100
보통
내재가치 · 3단계 구간 현재가 $56.66 실시간 · 적정 내재가치 구간 내

종합 밸류에이션 구간 · 보수적 $36–$40 / 적정 $52–$66 / 낙관적 $84–$90. $56.66 기준, 적정 내재가치 구간 내.

보고서 발행 시 $58.41（2026년 9월 20일）

재무 개요
시가총액US$330.29억
매출 (TTM)US$25.36억
EBITDAUS$15.57억
순이익률32.02%
ROE13.97%
PER (TTM)30.9
선행 PER29.41
PEG1.34
EPSUS$1.85
배당수익률1.58%
52주 범위US$34.56 – US$64.38
애널리스트 목표주가US$65.13
애널리스트 평가4.5 / 5

데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.

회사 소개

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

기본 정보

연혁

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.

업계 내 위치

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.

이 종목에 대한 리포트
50/100 보유 Royalty Pharma: $3.254bn of Portfolio Receipts and 48% Deal Share Meet a 24% Expiry Wall by 2030 and a $58.41 Price That Already Pays for the Platform Royalty Pharma is a specialty-finance platform whose loan book is denominated in molecules: it buys contractual percentages of other companies' drug sales, funds late-stage development in exchange for synthetic royalties, and collects near the top of the income statement while somebody else carries the commercial cost. 2025 Portfolio Receipts were $3.254bn against only $288m of cash operating and professional costs, and the company sourced 48% of announced biopharma-royalty transaction value over 2020-2025, but roughly 24% of 2025 Royalty Receipts sits on products whose royalty duration substantially ends by 2030, and hitting the $4.7bn 2030 target needs $2.0-2.5bn of deployment every year. Rating Hold: at $58.41 the shares are near 11.6 times estimated 2026 Portfolio Cash Flow but 19-23 times owner earnings once $1.1-1.4bn of replacement deployment is charged as economic maintenance, above the $46-50 conservative value, so the report waits for $36-40 before committing new capital. Royalty Pharma plcRPRX · 미국生物制药特许权2026년 9월 20일